SARS-CoV-2 Nucleocapsid Antibody (019) [Janelia Fluor® 635]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-12735JF635
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Key Product Details
Species Reactivity
SARS-CoV
Applications
ELISA, Western Blot
Label
Janelia Fluor 635
Antibody Source
Recombinant Monoclonal Rabbit IgG Clone # 019
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Recombinant SARS-CoV-2 Nucleocapsid Protein
Reactivity Notes
No cross-reactivity in ELISA with:
MERS-CoV Nucleoprotein protein
HCoV-229E Nucleoprotein protein
HCoV-NL63 Nucleoprotein protein
HCoV-HKU1(isolate N5) Nucleoprotein protein
HCoV-OC43 Nucleoprotein
MERS-CoV Nucleoprotein protein
HCoV-229E Nucleoprotein protein
HCoV-NL63 Nucleoprotein protein
HCoV-HKU1(isolate N5) Nucleoprotein protein
HCoV-OC43 Nucleoprotein
Specificity
Has cross-reactivity in ELISA with:SARS-CoV-2 Omicron (B.1.1.529) Nucleocapsid ProteinNo cross-reactivity in ELISA with:MERS-CoV Nucleocapsid proteinHCoV-229E Nucleocapsid proteinHCoV-NL63 Nucleocapsid proteinHCoV-HKU1(isolate N5) Nucleocapsid proteinHCoV-OC43 Nucleocapsid protein
Clonality
Monoclonal
Host
Rabbit
Isotype
IgG
Applications for SARS-CoV-2 Nucleocapsid Antibody (019) [Janelia Fluor® 635]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: SARS-CoV-2 Nucleocapsid
Following SARS-CoV-2 infection, B cells and T cells display an immune response against nucleocapsid protein and nucleocapsid-specific neutralizing antibodies are produced (5). Interestingly, a study of patients who have recovered from COVID-19 revealed that there were no neutralizing antibodies against nucleocapsid protein present; however, a high presence against neutralizing spike RBD antibodies were detected (5).
References
1. Pillay T. S. (2020). Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein. Journal of Clinical Pathology. https://doi.org/10.1136/jclinpath-2020-206658
2. Malik Y. A. (2020). Properties of Coronavirus and SARS-CoV-2. The Malaysian Journal of Pathology.
3. Zhu, G., Zhu, C., Zhu, Y., & Sun, F. (2020). Minireview of progress in the structural study of SARS-CoV-2 proteins. Current Research in Microbial Sciences. https://doi.org/10.1016/j.crmicr.2020.06.003
4. Uniprot (P0DTC9)
5. Shah, V. K., Firmal, P., Alam, A., Ganguly, D., & Chattopadhyay, S. (2020). Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2020.01949
Alternate Names
2019-nCoV N Protein, 2019-nCoV Nucleocapsid Protein, COVID-19 N protein, COVID-19 nucleocapsid protein, Human coronavirus Nucleoprotein, nucleocapsid phosphoprotein, Nucleocapsid protein, Nucleoprotein, ORF9; structural protein, SARS-CoV-2, SARS-CoV-2 Nucleocapsid protein, SARS-CoV-2 N protein, SARSCoV2 Nucleoprotein, Severe Acute Respiratory Syndrome Coronavirus 2 Nucleocapsid Protein
Gene Symbol
N
Additional SARS-CoV-2 Nucleocapsid Products
Product Documents for SARS-CoV-2 Nucleocapsid Antibody (019) [Janelia Fluor® 635]
Product Specific Notices for SARS-CoV-2 Nucleocapsid Antibody (019) [Janelia Fluor® 635]
Sold under license from the Howard Hughes Medical Institute, Janelia Research Campus.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...